LIO

Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of Million of Families Across America

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- SpeakerNancy Pelosi issued the following statement today in response toPresident Bush's veto of the stem cell bill: "Once again, the President has ignored the will of the Americanpeople, of leading medical researchers, and of a bipartisanmajority of the Congress. His cruel veto says 'no' to the hopes ofmillion of families across...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selectiveVEGF signaling inhibitor - shows over a quarter of patients aliveand progression- free at six months(1) CHICAGO, June 04, 2007 /PRNewswire/ -- Data for theinvestigational agent cediranib (AZD2171) were presented today atthe annual meeting of the American Society of Clinical Oncology(ASCO) from a study in patients with recurr...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO

MONTRÉAL, June 1, 2007 – Thallion Pharmaceuticals Inc.(TSX: TLN) announced today that preliminary data from its PhaseI/II clinical trial investigating ECO-4601 in advanced cancerpatients was published in abstract form as part of the AmericanSociety of Clinical Oncology (ASCO) Annual Meeting in Chicago,Illinois. In the Phase I dose escalation portion of the study, 14patients (te...

Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting

SAN DIEGO, May 14, 2007 /PRNewswire-FirstCall/ -- Shire plc ,the market leader in treatments for Attention-Deficit/HyperactivityDisorder (ADHD), announced that it will present key scientific dataon its ADHD treatment portfolio at the American PsychiatricAssociation (APA) annual meeting to be held May 19 to 24 in SanDiego. "The upcoming clinical research to be presented at APA reaff...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

Achillion Presents Positive Data on Novel Mechanism for Treating HCV at EASL Annual Meeting

-NS4A Antagonist Demonstrates Clinical Activity, a Novel Mechanismof Action and In Vitro Compatibility with other HCV Inhibitors- NEW HAVEN, Conn., April 16, 2007 /PRNewswire-FirstCall/ --Achillion Pharmaceuticals, Inc. today announced the presentation ofdata validating the clinical antiviral activity of one ofAchillion's NS4A antagonists, ACH-806, for the treatment ofhepatitis C virus (H...

Data from Investigator-Sponsored Trial of Oncophage Cancer Vaccine in Glioma Presented at American Association of Neurological Surgeons Annual Meeting

WASHINGTON--(BUSINESS WIRE)--Apr 16, 2007 - Antigenics Inc.(NASDAQ: AGEN) today announced an oral presentation of updated datafrom a Phase 1/2 investigator-sponsored trial of the company'sinvestigational cancer vaccine Oncophage(R) (vitespen) inrecurrent, high-grade glioma at the 75th annual meeting of theAmerican Association of Neurological Surgeons (AANS; abstract#606). Preliminary result...

Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying to Control It Later

LONDON, April 12, 2007--The costs of eradicatingpoliomyelitis from the remaining infected countries, while high inthe short term, are much lower than the long term costs of tryingto control infections without eradication. And a recently developedmonovalent vaccine is almost three times more effective againsttype 1 poliomyelitis than an existing trivalent vaccine. These are...

Trichomoniasis: Most Common Curable STD in U.S. Affects 7.4 Million Annually

April is STD Awareness Month: Time to Pay Attention to thisOverlooked Disease SAN ANTONIO, Texas, April 02, 2007 /PRNewswire/ -- DuringNational Sexually Transmitted Disease (STD) Awareness Month thisApril, Mission Pharmacal is urging increased awareness of, andtesting for, trichomoniasis (also known as "trich"), the mostcommon curable STD in the United States. Awareness of the conditionr...

Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiology's 56th Annual Scientific Session

Highlights Include First U.S. Clinical Data on XIENCE V EverolimusEluting Coronary Stent System and Six-Month Patient Follow-UpResults from the ABSORB Bioabsorbable Stent Clinical Study ABBOTT PARK, Ill., March 19, 2007 /PRNewswire-FirstCall/ --Abbott will present data from several studies across its broadvascular portfolio and pipeline during a number of late-breakingclinical...

Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice

PHILADELPHIA, March 15, 2007-- The cause of one notoriouschildhood disease, poliovirus, could be used to treat the ongoingthreat of another childhood disease, neuroblastoma. In the March 15issue of Cancer Research, researchers from Stony Brook Universityreport that an attenuated -- or non-virulent -- form of poliovirusis effective in obliterating neuroblastoma tumors in mice, evenwhen th...

Why Is Polio Spreading in Pakistan?

LEWISVILLE, Texas, March 8, 2007--The World Health Organizationhas released new figures that show that polio cases are rising inPakistan. So is this another instance where, as leftist groups constantlyclaim, the pharmaceutical industry is denying important vaccines topoor populations? Um, apparently not. According to London’s Guardiannewspaper, “parents of 24,00...

Actelion Announces Positive Study with Bosentan (Tracleer) in CTEPH

First-Ever Placebo-controlled Study in Inoperable ChronicThromboembolic Pulmonary Hypertension - Primary Endpoint ofReduction in Pulmonary Vascular Resistance Met - Six-Minute-walkTest Unchanged - Significant Effect on Dyspnoea Score andBiological Disease Marker ALLSCHWIL, Switzerland, March 5, 2007 -Actelion Ltd (SWX:ATLN) announced today the initial results from the doub...